Starpharma today released its Appendix 4C - Quarterly Cashflow report for the period ended 31 March 2012.

In this issue:

› Starpharma commences pivotal phase 3 VivaGel^® BV treatment trials

› Starpharma continues to build momentum as a leader in the sector

› Starpharma improves efficacy of leading chemotherapy drug docetaxel with dendrimers in breast cancer model

› Nanobiotechnology to reach $6 billion by 2017

Download: Shareholder Update: April 2012 ( pdf file, 1MB)